Figure 4.
EPHB4-CAR-T cells debulked rhabdomyosarcoma tumors in a murine xenograft model
We injected 2 × 106 Rh30-Luc cells into the dorsal area of SCID beige mice. 7 days later, 10 × 106 EPHB4-CAR-T cells or CD19-CAR-T cells (the expression of each CAR molecule was around 80%) were injected into the tail vein of each mouse. (A) Representative bioluminescent images of tumor growth over time in individual mice. (B) Kinetics of Rh30 xenograft progression in individual mice that had received either the CD19 (control) or EPHB4 CAR-T cells by IVIS imaging. (C) Survival analysis of EPHB4-CAR-T cell-treated mice and CD19-CAR-T cell-treated mice (CD19: N = 6; EPHB4: N = 6). (D) Mice treated with EPHB4-CAR-T cells did not show weight loss. (E) Human T cells in peripheral blood of mice on day 31. Representative dot plot data were shown.